Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
Lancet (London, England)|May 28, 2026
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b studyGavin Giovannoni, Laura Airas, Riley Bove, et al.
The New England Journal of Medicine|December 22, 2016
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisStephen L Hauser, Amit Bar-Or, Giancarlo Comi, et al.
Neurology|June 8, 2023
Polygenicity of Comorbid Depression in Multiple SclerosisKaarina Kowalec, Kathryn C Fitzgerald, Amber Salter, et al.
The New England Journal of Medicine|December 22, 2016
Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisXavier Montalban, Stephen L Hauser, Ludwig Kappos, et al.
Annals of Clinical and Translational Neurology|March 22, 2018
Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS studyDavid H Miller, Fred D Lublin, Maria Pia Sormani, et al.
Annals of Clinical and Translational Neurology|May 8, 2024
Polygenic liability for anxiety in association with comorbid anxiety in multiple sclerosisKaarina Kowalec, Arvid Harder, Casandra Dolovich, et al.
European Journal of Neurology|March 16, 2021
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registryHelmut Butzkueven, Tim Spelman, Dana Horakova, et al.
International Journal of MS Care|November 12, 2020
An International Standardized Magnetic Resonance Imaging Protocol for Diagnosis and Follow-up of Patients with Multiple Sclerosis: Advocacy, Dissemination, and Implementation StrategiesLori Saslow, David K B Li, June Halper, et al.
Annals of Neurology|August 7, 2025
Depression Polygenicity and Disease Activity and Disability Worsening in Multiple SclerosisAli Manouchehrinia, Kathryn C Fitzgerald, Amber Salter, et al.
Neurology|May 30, 2014
Defining the clinical course of multiple sclerosis: the 2013 revisionsFred D Lublin, Stephen C Reingold, Jeffrey A Cohen, et al.
Pageof 14